Eli Lilly says that it will not comply with a 2017 California law on drug pricing, and now the state senator who sponsored the bill is hitting back against the drug manufacturer, calling the company’s activities to promote its diabetes programs “disingenuous and offensive.”
Eli Lilly says that it will not comply with a 2017 California law on drug pricing, and now the state senator who sponsored the bill is hitting back against the drug manufacturer, calling the company’s activities to promote its diabetes programs “disingenuous and offensive.”
The law in question, SB 17, which was signed into law in October 2017, requires drug makers to provide to the state 60 days’ notice of price increases above 16% when combined with increases from the previous 2 years. Companies are also required to justify those increases, and insurers must provide information about how drug costs will affect premiums for health plan members. Drug companies are subject to a civil penalty if they do not comply.
In early 2018, Eil Lilly sent a letter to its registered purchases explaining that it was “not able” to provide the required information, and that it would await the outcome of a lawsuit challenging the constitutionality of the law before issuing any notices about its drug prices.
The lawsuit, filed by the pharmaceutical industry trade and lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA), claims that the law would force drug makers “…to publicly convey and implicitly endorse the state’s position that the manufacturers are to blame for the allegedly inflated prices of prescription drugs,” and seeks a declaration that the law violates the First Amendment, the Fourteenth Amendment, and the Commerce Clause.
Read more about PhRMA’s challenge to SB 17.
Meanwhile, Lilly has launched a program that it calls its Diabetes Solution Center, a helpline with representatives who review financial options with patients who have difficulty paying for their insulin products.
Lilly’s refusal to comply with the law, coupled with its launch of the helpline, has drawn ire from State Senator Ed Hernandez, OD, a Democrat who represents the district of West Covina. Last month, Hernandez penned a letter to Eli Lilly’s chairman and CEO, David A. Ricks, saying, “Your company’s egregious defiance of state law makes your promotion of a ‘Diabetes Solution Center’ even more disingenuous and offensive. If you would simply comply with SB 17, Californians would know when you hike the price of insulin.”
The letter, which was cosigned by representatives of the California Labor Federation, Health Access California, and the labor union Unite Here went on to say that “Californians shouldn’t have to plead their case to telephone operators,” and asked the drug maker to “simply lower the price” that it charges for its insulin products.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.